Literature DB >> 17195073

Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach.

Steven Haugbøl1, Lars H Pinborg, Haroon M Arfan, Vibe M Frøkjaer, Jacob Madsen, Tim B Dyrby, Claus Svarer, Gitte M Knudsen.   

Abstract

PURPOSE: To determine the reproducibility of measurements of brain 5-HT2A receptors with an [18F]altanserin PET bolus/infusion approach. Further, to estimate the sample size needed to detect regional differences between two groups and, finally, to evaluate how partial volume correction affects reproducibility and the required sample size.
METHODS: For assessment of the variability, six subjects were investigated with [18F]altanserin PET twice, at an interval of less than 2 weeks. The sample size required to detect a 20% difference was estimated from [18F]altanserin PET studies in 84 healthy subjects. Regions of interest were automatically delineated on co-registered MR and PET images.
RESULTS: In cortical brain regions with a high density of 5-HT2A receptors, the outcome parameter (binding potential, BP1) showed high reproducibility, with a median difference between the two group measurements of 6% (range 5-12%), whereas in regions with a low receptor density, BP1 reproducibility was lower, with a median difference of 17% (range 11-39%). Partial volume correction reduced the variability in the sample considerably. The sample size required to detect a 20% difference in brain regions with high receptor density is approximately 27, whereas for low receptor binding regions the required sample size is substantially higher.
CONCLUSION: This study demonstrates that [18F]altanserin PET with a bolus/infusion design has very low variability, particularly in larger brain regions with high 5-HT2A receptor density. Moreover, partial volume correction considerably reduces the sample size required to detect regional changes between groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17195073     DOI: 10.1007/s00259-006-0296-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  15 in total

1.  Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction.

Authors:  Mario Quarantelli; Karim Berkouk; Anna Prinster; Brigitte Landeau; Claus Svarer; Laszlo Balkay; Bruno Alfano; Arturo Brunetti; Jean-Claude Baron; Marco Salvatore
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

2.  Rapid automated algorithm for aligning and reslicing PET images.

Authors:  R P Woods; S R Cherry; J C Mazziotta
Journal:  J Comput Assist Tomogr       Date:  1992 Jul-Aug       Impact factor: 1.826

3.  Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects.

Authors:  H W Müller-Gärtner; J M Links; J L Prince; R N Bryan; E McVeigh; J P Leal; C Davatzikos; J J Frost
Journal:  J Cereb Blood Flow Metab       Date:  1992-07       Impact factor: 6.200

4.  PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin.

Authors:  C H van Dyck; P Z Tan; R M Baldwin; L A Amici; P K Garg; C K Ng; R Soufer; D S Charney; R B Innis
Journal:  J Nucl Med       Date:  2000-02       Impact factor: 10.057

5.  Performance characteristics of a whole-body PET scanner.

Authors:  T R DeGrado; T G Turkington; J J Williams; C W Stearns; J M Hoffman; R E Coleman
Journal:  J Nucl Med       Date:  1994-08       Impact factor: 10.057

6.  PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907.

Authors:  H Ito; S Nyberg; C Halldin; C Lundkvist; L Farde
Journal:  J Nucl Med       Date:  1998-01       Impact factor: 10.057

7.  Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain.

Authors:  G S Smith; J C Price; B J Lopresti; Y Huang; N Simpson; D Holt; N S Mason; C C Meltzer; R A Sweet; T Nichols; D Sashin; C A Mathis
Journal:  Synapse       Date:  1998-12       Impact factor: 2.562

8.  Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography.

Authors:  F Biver; S Goldman; A Luxen; M Monclus; M Forestini; J Mendlewicz; F Lotstra
Journal:  Eur J Nucl Med       Date:  1994-09

9.  Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls.

Authors:  B Sadzot; C Lemaire; P Maquet; E Salmon; A Plenevaux; C Degueldre; J P Hermanne; M Guillaume; R Cantineau; D Comar
Journal:  J Cereb Blood Flow Metab       Date:  1995-09       Impact factor: 6.200

10.  Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach.

Authors:  Lars H Pinborg; Karen H Adams; Claus Svarer; Søren Holm; Steen G Hasselbalch; Steven Haugbøl; Jacob Madsen; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2003-08       Impact factor: 6.200

View more
  12 in total

1.  Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.

Authors:  Hans Rasmussen; Bjorn H Ebdrup; David Erritzoe; Bodil Aggernaes; Bob Oranje; Jan Kalbitzer; Lars H Pinborg; William F C Baaré; Claus Svarer; Henrik Lublin; Gitte M Knudsen; Birte Glenthoj
Journal:  Psychopharmacology (Berl)       Date:  2010-07-08       Impact factor: 4.530

2.  Age, sex, and reproductive hormone effects on brain serotonin-1A and serotonin-2A receptor binding in a healthy population.

Authors:  Eydie L Moses-Kolko; Julie C Price; Nilesh Shah; Sarah Berga; Susan M Sereika; Patrick M Fisher; Rhaven Coleman; Carl Becker; N Scott Mason; Tammy Loucks; Carolyn C Meltzer
Journal:  Neuropsychopharmacology       Date:  2011-08-17       Impact factor: 7.853

3.  Suitability of [18F]altanserin and PET to determine 5-HT2A receptor availability in the rat brain: in vivo and in vitro validation of invasive and non-invasive kinetic models.

Authors:  Tina Kroll; David Elmenhorst; Andreas Matusch; Franziska Wedekind; Angela Weisshaupt; Simone Beer; Andreas Bauer
Journal:  Mol Imaging Biol       Date:  2013-03-01       Impact factor: 3.488

4.  Longitudinal assessment of cerebral 5-HT2A receptors in healthy elderly volunteers: an [18F]-altanserin PET study.

Authors:  Lisbeth Marner; Gitte M Knudsen; Steven Haugbøl; Søren Holm; William Baaré; Steen G Hasselbalch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-01       Impact factor: 9.236

5.  5-HT2A receptor density is decreased in the at-risk mental state.

Authors:  René Hurlemann; Andreas Matusch; Kai-Uwe Kuhn; Julia Berning; David Elmenhorst; Oliver Winz; Heike Kolsch; Karl Zilles; Michael Wagner; Wolfgang Maier; Andreas Bauer
Journal:  Psychopharmacology (Berl)       Date:  2007-09-27       Impact factor: 4.530

6.  Sleep deprivation increases cerebral serotonin 2A receptor binding in humans.

Authors:  David Elmenhorst; Tina Kroll; Andreas Matusch; Andreas Bauer
Journal:  Sleep       Date:  2012-12-01       Impact factor: 5.849

Review 7.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

8.  Validation and quantification of [18F]altanserin binding in the rat brain using blood input and reference tissue modeling.

Authors:  Patrick J Riss; Young T Hong; David Williamson; Daniele Caprioli; Sergey Sitnikov; Valentina Ferrari; Steve J Sawiak; Jean-Claude Baron; Jeffrey W Dalley; Tim D Fryer; Franklin I Aigbirhio
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-13       Impact factor: 6.200

Review 9.  Functional and molecular neuroimaging of menopause and hormone replacement therapy.

Authors:  Erika Comasco; Vibe G Frokjaer; Inger Sundström-Poromaa
Journal:  Front Neurosci       Date:  2014-12-08       Impact factor: 4.677

10.  Nature or nurture? Determining the heritability of human striatal dopamine function: an [18F]-DOPA PET study.

Authors:  Paul R A Stokes; Paul Shotbolt; Mitul A Mehta; Eric Turkheimer; Aaf Benecke; Caroline Copeland; Federico E Turkheimer; Anne R Lingford-Hughes; Oliver D Howes
Journal:  Neuropsychopharmacology       Date:  2012-10-24       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.